CARDIO-TTRansform randomized 1432 wild-type or hereditary ATTR-CM patients to eplontersen 45 mg vs placebo every 4 weeks, with a primary composite endpoint assessed through week 140. Real-world ...

Shares of AstraZeneca AZN fell nearly 8% in pre-market trading today after the company announced the failure of a phase III study evaluating Wainua (eplontersen) in patients with ...

AstraZeneca and Ionis both saw their stocks take a hit on 9 July following the ATTR-CM trial failure.

Transthyretin amyloidosis (ATTR) is a protein conformational disorder caused by the build-up of transthyretin, the protein carrying thyroxine and retinol in the bloodstream. While cardiomyopathy is a ...

Taking care of someone with cardiac amyloidosis can be challenging, but you’re not alone. In people with ATTR-CM, proteins called amyloids build up in the heart, which stiffens the muscle over time.

AstraZeneca reported a phase III failure for its ATTR-CM drug Wainua, shifting attention to competitors in this rare heart ...

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a serious and debilitating heart condition that may require a collaborative team of experts. ATTR-CM not only affects the heart, it also often impacts ...

Author(s)Ryan Haumschild, PharmD, MS, MBA, CPEL, Kevin Alexander, MD, FACC, FHFSA Welcome back to another AJMC Payer Perspectives series. In this opening episode titled, ‘Transthyretin Amyloid ...

Heart failure can be a scary diagnosis. But what if there’s something else going on that’s even harder to spot? Meet transthyretin cardiac amyloidosis (ATTR-CM)—a serious heart condition that is ...

SAN FRANCISCO, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today announced the initiation and design of its pivotal global Phase 3 trial (ATTRibute-CM) of AG10 in ...